01:04 , Jun 28, 2019 |  BC Extra  |  Financial News

June 27 Financial Quick Takes: Esperion gets $125M from Oberland in funding deal for cholesterol candidates; plus Woodford, PanTheryx and Castle

Esperion, Oberland strike funding deal ahead of bempedoic acid launch  Esperion Therapeutics Inc. (NASDAQ:ESPR) forged a funding agreement with Oberland Capital tied to revenues from the sale of products containing the biotech's cholesterol-lowering candidate bempedoic...
00:09 , Jun 27, 2019 |  BC Extra  |  Financial News

June 26 Financial Quick Takes: Adaptive prices upsized IPO; plus BridgeBio, Medicines Co., Global Blood, Odonate

Adaptive raises $300M in IPO  Adaptive Biotechnologies Inc. (NASDAQ:ADPT) raised $300 million through the sale of 15 million shares at $20 in an IPO on NASDAQ. The deal price values the computation immunology and diagnostics...
22:58 , Jun 18, 2019 |  BC Extra  |  Financial News

June 18 Financial Quick Takes: Biohaven sinks on fund-raising news; plus IPO trio sets terms

Amid buyout rumors, Biohaven proposes follow-on  Biohaven Pharmaceutical Holding Co. Ltd. (NYSE:BHVN) lost $13.54 (24%) to $43.83 on Tuesday, shedding more than half a billion dollars in market cap, after it proposed to raise $300...
20:36 , May 31, 2019 |  BC Extra  |  Financial News

New IPO filings include Adaptive, Morphic

Immunosequencing company Adaptive and integrin company Morphic each filed for IPOs on NASDAQ Thursday, while antipsychotic therapy developer Karuna revealed details of its planned listing on the exchange on Friday. Adaptive Biotechnologies Corp. (Seattle, Wash.)...
18:57 , Apr 25, 2019 |  BC Extra  |  Financial News

Gritstone raises $75M in follow-on as second neoantigen immunotherapy heads to clinic

Days after saying it plans to accelerate its second neoantigen immunotherapy into the clinic, Gritstone has raised $74.8 million in a follow-on. Gritstone Oncology Inc. (NASDAQ:GRTS) sold $6.5 million shares at $11.50 in the deal,...
21:34 , Apr 19, 2019 |  BC Week In Review  |  Clinical News

Eiger raises $49.5M following Phase II HDV readout for Lambda

Eiger reported data from the Phase II LIMT HDV trial showing that high-dose Lambda as monotherapy led to a 36% durable virologic response rate at 24 weeks following treatment among 14 evaluable patients with chronic...
21:19 , Apr 10, 2019 |  BC Extra  |  Financial News

Rare genetic disease company Homology raises $125M follow-on

Homology raised $125 million in a follow-on priced late Tuesday to advance its pipeline of gene therapies. Homology Medicines Inc. (NASDAQ:FIXX) sold 5.5 million shares at $22.50. The price represents a 24% discount to the...
18:47 , Feb 15, 2019 |  BC Week In Review  |  Financial News

MacroGenics raises $110M in follow-on

Days after its shares more than doubled based on a Phase III breast cancer readout, MacroGenics Inc. (NASDAQ:MGNX) raised $110 million in a follow-on. MacroGenics sold 5.5 million shares at $20, pricing at a 5%...
18:13 , Feb 13, 2019 |  BC Extra  |  Financial News

MacroGenics raises $110M following breast cancer data

Days after its shares more than doubled based on a Phase III breast cancer readout, MacroGenics Inc. (NASDAQ:MGNX) raised $110 million in a follow-on. MacroGenics sold 5.5 million shares at $20, pricing at a 5%...
17:58 , Oct 26, 2018 |  BC Week In Review  |  Financial News

Eiger prices $43.4M follow-on

Orphan disease company Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) raised $43.5 million through the sale of 4.3 million shares at $10.35 in a follow-on underwritten by BTIG. The price is a 13% discount to the company's close...